FOR IMMEDIATE RELEASE
Friday, July 16, 2010
A research project to identify all the surface proteins of USA300—the most common community-associated strain of the methicillin-resistant form of the bacterium Staphylococcus aureus (MRSA)—has resulted in the identification and isolation of a plentiful new toxin that laboratory studies indicate is a potent killer of human immune cells. Scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, say the toxin could be a key factor in the severity of MRSA infections in otherwise healthy people. The toxin, named LukGH, consists of two small proteins found on the surface of the bacteria and is secreted freely into the surrounding environment.
The scientists identified 113 proteins associated with the surface of USA300 and began to examine the role of the previously uncharacterized proteins. S. aureus surface proteins are key indicators of how the pathogen will respond to contact with immune system cells, such as neutrophils, which the body produces in large numbers to kill invading microbes. Some proteins can aggressively attack these immune cells, and the demise of the neutrophils ultimately enables the bacteria to replicate and thrive. When the LukGH toxin was removed from USA300, studies showed that the strain caused little to no damage to human neutrophils. With the toxin present, the bacteria began forming pores in neutrophils which eventually led to their destruction.
The scientists say they do not know the full contribution of LukGH to the severity of MRSA infection. However, LukGH is the only MRSA toxin currently known to promote destruction of human neutrophils after the bacteria have been ingested by the immune cells designed to destroy them. Using animal models of MRSA infection, the NIH team is continuing to study the role of LukGH in disease.
C Ventura et al. Identification of a novel Staphylococcus aureus two-component leukotoxin using cell surface proteomics. PLoS One DOI: 10.1371/journal.pone.0011634 (2010).
Frank DeLeo, Ph.D., Chief of the Laboratory of Human Bacterial Pathogenesis, is available to comment on this article.
To schedule interviews, please contact Ken Pekoc, 301-402-1663, email@example.com.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of
infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News
releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S.
Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research,
and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery Into Health ®
back to top
Last Updated July 16, 2010
Last Reviewed July 16, 2010